Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
Zhibo Zhang(Chinese PLA General Hospital), Jinliang Wang(Chinese PLA General Hospital)
Cited by 54
Related Papers
Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis
|Frontiers in Oncology|2021|125
The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors
|Clinical Medicine Insights Oncology|2021|64